We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » RiskMAP GUIDANCES MAY SLOW DRUG AVAILABILITY
RiskMAP GUIDANCES MAY SLOW DRUG AVAILABILITY
July 16, 2004
Industry group says that even though the FDA’s promulgation of three draft guidance documents on risk assessment and minimization will go a long way in establishing a framework for industry and the agency, some components of the guidances may actually delay the availability of new and beneficial drugs.